Screening for hepatocellular carcinoma and cholangiocarcinoma: Can biomarkers replace imaging?
作者信息
Lozada Maria E, Chaiteerakij Roongruedee, Roberts Lewis R
机构信息
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN, 55905.
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN, 55905 and Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok 10330, Thailand.
出版信息
Curr Hepatol Rep. 2015 Jun;14(2):128-138. doi: 10.1007/s11901-015-0261-y.
Abstract
摘要
相似文献
1
Screening for hepatocellular carcinoma and cholangiocarcinoma: Can biomarkers replace imaging?肝细胞癌和胆管癌的筛查：生物标志物能否取代影像学检查？
Curr Hepatol Rep. 2015 Jun;14(2):128-138. doi: 10.1007/s11901-015-0261-y.
2
Imaging of combined hepatocellular-cholangiocarcinoma in cirrhosis and risk of false diagnosis of hepatocellular carcinoma.肝硬化中肝细胞癌-胆管细胞癌混合癌的影像学表现与肝细胞癌误诊风险。
United European Gastroenterol J. 2019 Feb;7(1):69-77. doi: 10.1177/2050640618815378. Epub 2018 Nov 22.
3
Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma.胆管腺瘤可能是小胆管型肝内胆管癌的前驱病变。
Histopathology. 2021 Jan;78(2):310-320. doi: 10.1111/his.14222. Epub 2020 Sep 15.
4
[Advances in imaging diagnosis of mixed-type liver cancer].
Zhonghua Gan Zang Bing Za Zhi. 2023 Feb 20;31(2):202-206. doi: 10.3760/cma.j.cn501113-20220303-00106.
5
Contrast-enhanced ultrasound in association with serum biomarkers for differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma.超声造影联合血清生物标志物鉴别肝细胞胆管癌与肝细胞癌及肝内胆管癌
World J Gastroenterol. 2020 Dec 14;26(46):7325-7337. doi: 10.3748/wjg.v26.i46.7325.
6
The Changing Face of the Diagnosis of Chronic and Malignant Liver Diseases: Potential New Biomarkers.慢性和恶性肝脏疾病诊断的变化面貌：潜在的新生物标志物。
Ann Hepatol. 2018 January-February;17(1):14-17. doi: 10.5604/01.3001.0010.7531.
7
Small molecule metabolite biomarkers for hepatocellular carcinoma with bile duct tumor thrombus diagnosis.用于胆管癌栓型肝细胞癌诊断的小分子代谢生物标志物。
Sci Rep. 2018 Feb 19;8(1):3309. doi: 10.1038/s41598-018-21595-4.
8
Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma.免疫组化染色多梳蛋白组蛋白 EZH2 和衰老标志物 p16INK4a 可能有助于鉴别胆毛细胆管细胞癌与胆管反应和胆管腺瘤。
Am J Surg Pathol. 2014 Mar;38(3):364-9. doi: 10.1097/PAS.0000000000000125.
9
Imaging approach to hepatocellular carcinoma, cholangiocarcinoma, and metastatic colorectal cancer.肝细胞癌、胆管癌和转移性结直肠癌的影像学检查方法
Surg Oncol Clin N Am. 2015 Jan;24(1):19-40. doi: 10.1016/j.soc.2014.09.002. Epub 2014 Oct 11.
10
Combined hepatocellular carcinoma-cholangiocarcinoma: MRI features correlated with tumor biomarkers and prognosis.混合型肝细胞癌-胆管细胞癌：与肿瘤标志物和预后相关的 MRI 特征。
Eur Radiol. 2022 Jan;32(1):78-88. doi: 10.1007/s00330-021-08188-y. Epub 2021 Jul 19.
引用本文的文献
1
Comparison between Brush Cytology and Forceps Biopsy under Fluoroscopic Guidance for the Diagnosis of Proximal Cholangiocarcinoma.荧光镜引导下刷检细胞学与钳取活检在近端胆管癌诊断中的比较
Middle East J Dig Dis. 2020 Oct;12(4):246-251. doi: 10.34172/mejdd.2020.189.
2
Serum coiled-coil domain containing 25 protein as a potential screening/diagnostic biomarker for cholangiocarcinoma.血清卷曲螺旋结构域包含蛋白25作为胆管癌潜在的筛查/诊断生物标志物。
Oncol Lett. 2020 Jan;19(1):930-942. doi: 10.3892/ol.2019.11162. Epub 2019 Nov 29.
3
Cholangiocarcinoma: a guide for the nonspecialist.胆管癌：非专科医生指南
Int J Gen Med. 2018 Dec 20;12:13-23. doi: 10.2147/IJGM.S186854. eCollection 2019.
4
Biomarker development for hepatocellular carcinoma early detection: current and future perspectives.肝细胞癌早期检测的生物标志物开发：现状与未来展望
Hepat Oncol. 2017 Oct;4(4):111-122. doi: 10.2217/hep-2017-0019. Epub 2017 Nov 17.
5
Biomarkers for Hepatocellular Carcinoma.肝细胞癌的生物标志物
Gastroenterol Hepatol (N Y). 2016 Apr;12(4):252-5.
本文引用的文献
1
Biomarkers in cholangiocarcinoma.胆管癌中的生物标志物
Clin Liver Dis (Hoboken). 2014 May 27;3(5):101-103. doi: 10.1002/cld.345. eCollection 2014 May.
2
Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation.用于预测肝移植后肝细胞癌复发的生物标志物与米兰标准的组合
Liver Transpl. 2015 May;21(5):599-606. doi: 10.1002/lt.24117.
3
Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study.肝细胞癌从诊断到死亡的全球管理模式：BRIDGE研究
Liver Int. 2015 Sep;35(9):2155-66. doi: 10.1111/liv.12818. Epub 2015 Mar 25.
4
DNAJB1-PRKACA is specific for fibrolamellar carcinoma.DNAJB1-PRKACA对纤维板层癌具有特异性。
Mod Pathol. 2015 Jun;28(6):822-9. doi: 10.1038/modpathol.2015.4. Epub 2015 Feb 20.
5
Unique genomic profile of fibrolamellar hepatocellular carcinoma.纤维板层型肝细胞癌的独特基因组图谱。
Gastroenterology. 2015 Apr;148(4):806-18.e10. doi: 10.1053/j.gastro.2014.12.028. Epub 2014 Dec 31.
6
Epithelium-Specific ETS (ESE)-1 upregulated GP73 expression in hepatocellular carcinoma cells.上皮特异性ETS（ESE）-1上调了肝癌细胞中GP73的表达。
Cell Biosci. 2014 Dec 8;4(1):76. doi: 10.1186/2045-3701-4-76. eCollection 2014.
7
Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma.可溶性Axl的多中心分析揭示了其对极早期肝细胞癌的诊断价值。
Int J Cancer. 2015 Jul 15;137(2):385-394. doi: 10.1002/ijc.29394. Epub 2015 Jan 13.
8
Multi-target stool DNA test: a new high bar for noninvasive screening.多靶点粪便DNA检测：无创筛查的新高标准。
Dig Dis Sci. 2015 Mar;60(3):623-33. doi: 10.1007/s10620-014-3451-5. Epub 2014 Dec 10.
9
Serum CYFRA 21-1 in Biliary Tract Cancers: A Reliable Biomarker for Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma.血清CYFRA 21-1在胆道癌中的作用：胆囊癌和肝内胆管癌的可靠生物标志物
Dig Dis Sci. 2015 May;60(5):1273-83. doi: 10.1007/s10620-014-3472-0. Epub 2014 Dec 9.
10
Problem of hepatocellular carcinoma in West Africa.西非肝细胞癌问题。
World J Hepatol. 2014 Nov 27;6(11):783-92. doi: 10.4254/wjh.v6.i11.783.
Zotero 插件